The Belport Company Inc., DBA Gingi-Pak appears in FDA device records as a Camarillo, California applicant for dental products. The supplied collection holds one linked 510(k) record, K262775 for AquaVance Clear Fluoride Treatment, decided substantially equivalent on 2026-10-27. A separate FDA decision letter documents Gingi-Aid Gel under K211419. The two filings show an applicant working across fluoride varnish and gingival retraction product codes rather than a single device line. [1][4][5]
AquaVance Clear Fluoride Treatment and K262775
K262775 covers AquaVance Clear Fluoride Treatment, submitted by The Belport Company Inc., DBA Gingi-Pak from 4825 Calle Alto, Camarillo, California. FDA received the traditional 510(k) on 2026-08-05 and issued a substantially equivalent decision on 2026-10-27. The record lists product code LBH, regulation 872.3260, classification name Varnish, Cavity, device class 2, and the dental advisory committee. A summary statement was filed and the submission was not third-party reviewed. [1][4]
The filing address in the FDA record is a submission address, not a verified headquarters. The record identifies Daniel Gallegos as the applicant contact. No manufacturing site, contract manufacturer or distribution arrangement for AquaVance Clear Fluoride Treatment is documented in the public documents. [1][4]
Gingi-Aid Gel and K211419
An FDA substantial equivalence determination dated January 10, 2022 addresses Gingi-Aid Gel, submitted by Belport Company, Inc., Gingi-Pak, with correspondence directed to Mohammed Islam, Director of R&D, at the Camarillo address. The letter lists regulatory class as unclassified and product code MVL. The stated indications describe gingival retraction before impression making and control of bleeding and gingival oozing in restorative and operative dentistry when used with gingival retraction cords. [5]
The accompanying 510(k) summary names Gingi-Pak, a Division of Belport Co., as submitter, with Xiaowen Xu as contact person and a summary prepared 07/08/2020. The device trade name appears as GingiAid. These details establish the applicant-division relationship for that submission; they do not establish ownership of any other entity. [5]
Company Identity and Published Claims
Gingi-Pak's own website states that since 1955 it has delivered soft tissue management products and continues as part of Pac-Dent International. The same site lists FDA Registered, ISO 13485 and Authorized Dealers Only as company-stated attributes, and says products are sold exclusively through authorized dental distributors. These are publisher claims, not independently verified certifications or channel facts. [3]
The site also states 30+ years of innovation, availability in 50+ countries and use by 10,000+ dental practices. Those figures originate with the company and are not corroborated by the FDA records in this collection. The FDA applicant name and the website brand name refer to the same commercial identity, while the Pac-Dent International relationship rests on the website statement alone. [3]
What the Filing Record Shows
The supplied portfolio snapshot, retrieved 2026-11-20, contains one linked record, a 510(k) with a substantially equivalent decision; the sample decision count is likewise one substantially equivalent decision. This is a snapshot of supplied filings, not a measure of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]
The FDA 510(k) final decisions feed for the period since October 01, 2026 lists unrelated dental and other applicants, including a mouth guard submission from Dongguan Yiyao Science & Technology Development Co., Ltd. and a catheter submission from Aesculap, Inc. Those entries provide context for the review period and do not describe Gingi-Pak filings. [2]
